Abstract
Persistent pulmonary hypertension of the newborn (PPHN) is characterized by elevated pulmonary vascular resistance resulting in right-to-left shunting of blood and hypoxemia. PPHN is often secondary to parenchymal lung disease (such as meconium aspiration syndrome, pneumonia or respiratory distress syndrome) or lung hypoplasia (with congenital diaphragmatic hernia or oligohydramnios) but can also be idiopathic. The diagnosis of PPHN is based on clinical evidence of labile hypoxemia often associated with differential cyanosis. The diagnosis is confirmed by the echocardiographic demonstration of – (a) right-to-left or bidirectional shunt at the ductus or foramen ovale and/or, (b) flattening or leftward deviation of the interventricular septum and/or, (c) tricuspid regurgitation, and finally (d) absence of structural heart disease. Management strategies include optimal oxygenation, avoiding respiratory and metabolic acidosis, blood pressure stabilization, sedation and pulmonary vasodilator therapy. Failure of these measures would lead to consideration of extracorporeal membrane oxygenation (ECMO); however decreased need for this rescue therapy has been documented with advances in medical management. While trends also note improved survival, long-term neurodevelopmental disabilities such as deafness and learning disabilities remain a concern in many infants with severe PPHN.Funded by: 1R01HD072929-0 (SL)
Highlights
Persistent pulmonary hypertension of newborn (PPHN) is secondary to failure of normal circulatory transition at birth
Even though pulmonary vascular cross-sectional area increases with fetal lung growth, pulmonary vascular resistance (PVR) increases with gestational age when corrected for lung or body weight, suggesting that pulmonary vascular tone increases during late gestation
Over the last two decades, management of infants with PPHN has included improved with improved ventilation strategies to optimize lung recruitment, provide “gentle” ventilation and minimize oxygen toxicity paired with the therapeutic use of surfactant and Inhaled Nitric Oxide (iNO)
Summary
Persistent pulmonary hypertension of newborn (PPHN) is secondary to failure of normal circulatory transition at birth. Maladaption/Parenchymal lung diseases resulting in secondary PPHN a) Meconium aspiration syndrome (MAS) in newborns leads to acute respiratory failure with a mortality of up to 10% [29].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.